CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Publication Type:

Journal Article


The New England journal of medicine, Volume 369, Issue 13, p.1227-36 (2013)


2013, Administration, Oral, Adult, Antiviral Agents, Center-Authored Paper, Clinical Research Division, CYTOMEGALOVIRUS, Cytomegalovirus Infections, Cytosine, Diarrhea, DNA, Viral, Dose-Response Relationship, Drug, Double-Blind Method, Female, hematopoietic stem cell transplantation, Humans, Incidence, Male, October 2013, Organophosphonates, Polymerase Chain Reaction, Transplantation, Homologous, Vaccine and Infectious Disease Division


The use of available antiviral agents for the prevention of cytomegalovirus (CMV) disease is limited by frequent toxic effects and the emergence of resistance. CMX001 has potent in vitro activity against CMV and other double-stranded DNA viruses. We evaluated the safety and anti-CMV activity of CMX001 in patients who had undergone allogeneic hematopoietic-cell transplantation.